Curanex Pharmaceuticals (CURX) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($6.9 million vs $6.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CURX | MTVA |
|---|---|---|
| Share price | $4.41 | $1.01 |
| Market cap | $6.92M | $6.81M |
| 1-day change | -0.67% | -7.34% |
| EPS (TTM) | $-8.78 | $-2.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-4.23M | $-12.97M |
| 52-week high | $13.34 | $13.42 |
| 52-week low | $3.58 | $0.966 |
| Distance from 52-week high | -66.94% | -92.47% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1813.86% |
| Average volume | 17.83K | 113.44K |
| Shares outstanding | 1.57M | 6.74M |
| Employees | 6 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
CURX vs MTVA FAQ
Which is bigger, Curanex Pharmaceuticals or MetaVia?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $6.92M compared with $6.81M for MetaVia (MTVA).
Are Curanex Pharmaceuticals and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.